Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Hiroto Inaba, MD PhD, John C Panetta, PhD, Daelynn R Buelow, PhD, Raul C. Ribeiro, MD, John R. Eckardt, MD, Sharyn D Baker, PharmD, PhD

Blood (2016) 128 (22): 3937.

https://doi.org/10.1182/blood.V128.22.3937.3937

Published: 2016

Journal Articles

Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML

Daelynn R Buelow, PhD, Stanley Pounds, PhD, Yong-Dong Wang, Lei Shi, PhD, Yongjin Li, PhD, David Finkelstein, Sheila A Shurtleff, PhD, Geoffrey A. Neale, PhD, Hiroto Inaba, MD PhD, Raul C. Ribeiro, MD, Dominique Garrison, Shelley Orwick, BS, James S. Blachly, MD, John C. Byrd, MD, Karl Kroll, Tanja A. Gruber, MD PhD, Jeffrey E Rubnitz, MD PhD, Sharyn D Baker, PharmD, PhD

Blood (2016) 128 (22): 2838.

https://doi.org/10.1182/blood.V128.22.2838.2838

Published: 2016

Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3695.

https://doi.org/10.1182/blood.V126.23.3695.3695

Published: 2015

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)

Jolieke G van Oosterwijk, PhD, Eric I Zimmerman, PhD, Yong-Dong Wang, PhD, Shelley Orwick, Aksana Vasilyeva, PhD, Katja Schuster, PhD, Abhijit Ramachandran, PhD, Hiroto Inaba, MD PhD, Sharyn D Baker, PharmD, PhD

Blood (2014) 124 (21): 3620.

https://doi.org/10.1182/blood.V124.21.3620.3620

Published: 2014

Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD

Blood (2013) 122 (21): 2680.

https://doi.org/10.1182/blood.V122.21.2680.2680

Published: 2013

Journal Articles

Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.

Hiroto Inaba, MD, PhD, Jeffrey E Rubnitz, MD, PhD, Elaine Coustan-Smith, MS, Lie Li, Brian D Furmanski, PhD, Gerard P Mascara, Sheila A Shurtleff, PhD, Stanley B Pounds, PhD, Ching-Hon Pui, MD, Raul C Ribeiro, MD, Dario Campana, MD, PhD, Sharyn D Baker, PharmD, PhD

Blood (2010) 116 (21): 1073.

https://doi.org/10.1182/blood.V116.21.1073.1073

Published: 2010

Journal Articles

Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.

Akira Shimada, MD, PhD, Shelley Orwick, Hiroyuki Fujisaki, MD., PhD, Dario Campana, MD., PhD, Sharyn D. Baker, PharmD., PhD

Blood (2008) 112 (11): 1630.

https://doi.org/10.1182/blood.V112.11.1630.1630

Published: 2008

NARROW

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.

Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML)

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.

Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only